| Name | dopamine D2 receptor |
|---|---|
| Synonyms | D(2) dopamine receptor; D2DR; D2R; DRD 2; DRD2; Dopamine D2 receptor; Dopamine receptor D2; Dopamine D2 receptors… |
| Name | nicotine |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 19154629 | Kim SE, Han SM: Nicotine- and methamphetamine-induced release evaluated with in-vivo binding of radiolabelled raclopride to dopamine D2 receptors: comparison with in-vivo microdialysis data. Int J Neuropsychopharmacol. 2009 Jul;12(6):833-41. Epub 2009 Jan 20. |
81(1,1,1,1) | Details |
| 19406037 | Naha N, Lee HY, Hwang JS, Bahk JY, Park MS, Lee SY, Kim SH, Kim MO: Nicotine tolerance to PC12 cell line: acute and chronic exposures modulate dopamine D2 receptor and tyrosine hydroxylase expression. Neurol Res. 2009 Apr;31(3):289-99. |
81(1,1,1,1) | Details |
| 19273465 | Munafo MR, Johnstone EC, Murphy MF, Aveyard P: Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. Nicotine Tob Res. 2009 Apr;11(4):404-7. Epub 2009 Mar 8. INTRODUCTION: We previously reported evidence that the T allele of the type-2 receptor (DRD2) rs1800497 polymorphism is associated with improved response to nicotine replacement therapy (NRT) relative to placebo and that this association may only be present in females. |
38(0,1,2,3) | Details |
| 19961902 | Knott V, Millar A, Fisher D, Albert P: Effects of nicotine on the amplitude and gating of the auditory P50 and its influence by dopamine D2 receptor gene polymorphism. Neuroscience. 2010 Mar 10;166(1):145-56. Epub 2009 Dec 2. In a randomized, double-blind, placebo-controlled design with 24 non-smokers, this study examined the influence of TaqIA dopamine D2 receptor gene polymorphisms on P50 and its inhibition during nicotine gum (6 mg) administration. |
37(0,1,2,2) | Details |
| 19904802 | Kobiella A, Vollstadt-Klein S, Buhler M, Graf C, Buchholz HG, Bernow N, Yakushev IY, Landvogt C, Schreckenberger M, Grunder G, Bartenstein P, Fehr C, Smolka MN: Human dopamine receptor D2/D3 availability predicts amygdala reactivity to unpleasant stimuli. Hum Brain Mapp. 2009 Nov 10. To address this issue, we measured DA D2/D3 receptor (DRD2/3) availability in twenty-eight healthy men (nicotine-dependent smokers and never-smokers) using positron emission tomography with [(18) F] fallypride. |
35(0,1,1,5) | Details |
| 19940429 | Blum K, Chen TJ, Downs BW, Bowirrat A, Waite RL, Braverman ER, Madigan M, Oscar-Berman M, DiNubile N, Stice E, Giordano J, Morse S, Gold M: Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART). Postgrad Med. 2009 Nov;121(6):176-96. PROPOSAL AND CONCLUSION: We propose that low D2 receptor density and polymorphisms of the D2 gene are associated with risk for relapse of substance abuse, including alcohol dependence, heroin craving, cocaine dependence, methamphetamine abuse, nicotine sensitization, and craving. Another therapeutic conundrum relates to the paradoxical finding that the dopaminergic agonist bromocriptine induces stronger activation of brain reward circuitry in individuals who carry the DRD2 A1 allele compared with DRD2 A2 allele carriers. |
5(0,0,0,5) | Details |
| 19308877 | Wernicke C, Reese J, Kraschewski A, Winterer G, Rommelspacher H, Gallinat J: Distinct haplogenotypes of the dopamine D2 receptor gene are associated with non-smoking behaviour and daily cigarette consumption. Pharmacopsychiatry. 2009 Mar;42(2):41-50. Epub 2009 Mar 23. INTRODUCTION: systems in the CNS are decisively implicated in the motivational and rewarding properties of nicotine. |
5(0,0,0,5) | Details |
| 20350135 | Breitling LP, Twardella D, Hoffmann MM, Witt SH, Treutlein J, Brenner H: Prospective association of -related polymorphisms with smoking cessation in general care. Pharmacogenomics. 2010 Apr;11(4):527-36. MATERIALS & METHODS: We examined genotypes at two -related loci, DRD2/ANKK1 (rs1800497) and DBH (rs77905), in 577 heavy smokers participating in a prospective study of smoking cessation in general care in Germany. |
4(0,0,0,4) | Details |
| 19014506 | Blum K, Chen AL, Chen TJ, Braverman ER, Reinking J, Blum SH, Cassel K, Downs BW, Waite RL, Williams L, Prihoda TJ, Kerner MM, Palomo T, Comings DE, Tung H, Rhoades P, Oscar-Berman M: Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theor Biol Med Model. 2008 Nov 12;5:24. BACKGROUND AND HYPOTHESIS: Based on neurochemical and genetic evidence, we suggest that both prevention and treatment of multiple addictions, such as dependence to nicotine and should involve a biphasic approach. Thus, a reduced number of DA receptors, due to carrying the DRD2 A1 allelic genotype, results in excessive craving behavior; whereas a normal or sufficient amount of DA receptors results in low craving behavior. |
2(0,0,0,2) | Details |
| 19842028 | Clague J, Cinciripini P, Blalock J, Wu X, Hudmon KS: The D2 receptor gene and nicotine dependence among bladder cancer patients and controls. Behav Genet. 2010 Jan;40(1):49-58. Epub 2009 Oct 15. To investigate further the relationships between the DRD2 genotypes, cigarette use and nicotine dependence, we examined the prevalence of polymorphisms in the TaqIA (A1 and A2) and the TaqIB (B1 and B2) alleles among a series of 608 non-Hispanic White bladder cancer patients and 608 matched controls. |
2(0,0,0,2) | Details |
| 19220487 | Evans DE, Park JY, Maxfield N, Drobes DJ: Neurocognitive variation in smoking behavior and withdrawal: genetic and affective moderators. Genes Brain Behav. 2009 Feb;8(1):86-96. A burgeoning literature suggests that attentional factors are associated with smoking behavior (e.g. direct nicotine effects and smoking withdrawal). Carrying the A1 allele at the dopamine receptor D2 (DRD2) Taq1A polymorphism site moderated the effects of withdrawal on nogo P3 amplitude, suggesting the A1 allele is a vulnerability marker for withdrawal-related attentional deficits. |
2(0,0,0,2) | Details |
| 19494806 | Bergen AW, Conti DV, Van Den Berg D, Lee W, Liu J, Li D, Guo N, Mi H, Thomas PD, Lessov-Schlaggar CN, Krasnow R, He Y, Nishita D, Jiang R, McClure JB, Tildesley E, Hops H, Tyndale RF, Benowitz NL, Lerman C, Swan GE: genes and nicotine dependence in treatment-seeking and community smokers. Neuropsychopharmacology. 2009 Sep;34(10):2252-64. Epub 2009 Jun 3. DRD2, SLC6A3, and NR4A2 SNPs with adjusted P-values <0.10 were considered sufficiently noteworthy to justify further genetic, bioinformatic, and literature analyses. |
2(0,0,0,2) | Details |
| 19179847 | Le Foll B, Gallo A, Le Strat Y, Lu L, Gorwood P: Genetics of receptors and drug addiction: a comprehensive review. Behav Pharmacol. 2009 Feb;20(1):1-17. Addictive substances, such as opioids, psychostimulants and nicotine, induce pleasant states or relieve distress, effects that contribute to their recreational use. Here, we will review the information collected implicating the receptors of the D1 family (DRD1 and DRD5) and of the D2 family (DRD2, DRD3 and DRD4) in drug addiction. |
2(0,0,0,2) | Details |
| 19413407 | Gilbert DG, Zuo Y, Rabinovich NE, Riise H, Needham R, Huggenvik JI: Neurotransmission-related genetic polymorphisms, negative affectivity traits, and gender predict tobacco abstinence symptoms across 44 days with and without nicotine patch. J Abnorm Psychol. 2009 May;118(2):322-34. NRT reduced NA to a greater extent in DRD2 A1 carriers than in A2A2 individuals during the 1st 2 weeks of treatment (when on the 21-mg patch); however, A1 carriers experienced a renewal of NA symptoms when switched to the 7-mg patch and when off the patch, while A2A2 individuals continued to benefit from NRT. |
1(0,0,0,1) | Details |
| 20033907 | Kim SH, Han DH, Joo SY, Min KJ: The effect of partial agonists on the nicotine dependency in patients with schizophrenia. Hum Psychopharmacol. 2010 Mar;25(2):187-90. CONCLUSIONS: The effects of a partial agonist of the dopamine D2 receptor, may reduce the severity of nicotine dependence in schizophrenic patients. |
1(0,0,0,1) | Details |
| 19720621 | Zhao-Shea R, Cohen BN, Just H, McClure-Begley T, Whiteaker P, Grady SR, Salminen O, Gardner PD, Lester HA, Tapper AR: Dopamine D2-receptor activation elicits akinesia, rigidity, catalepsy, and tremor in mice expressing hypersensitive {alpha}4 nicotinic receptors via a cholinergic-dependent mechanism. FASEB J. 2010 Jan;24(1):49-57. Epub 2009 Aug 31. Highlighting the importance of the cholinergic system in this mouse model, inhibiting the effects of by blocking muscarinic receptors, or by selectively activating hypersensitive nAChRs with nicotine, rescued motor symptoms. |
1(0,0,0,1) | Details |
| 19095220 | Le Foll B, Chefer SI, Kimes AS, Shumway D, Stein EA, Mukhin AG, Goldberg SR: Baseline expression of alpha4beta2* nicotinic acetylcholine receptors predicts motivation to self-administer nicotine. Biol Psychiatry. 2009 Apr 15;65(8):714-6. Epub 2008 Dec 18. Similarly, it has been previously shown that low levels of D (2) receptors (DRD2) are associated with a higher preference for psychostimulant use in humans and nonhuman primates. |
1(0,0,0,1) | Details |
| 20133381 | David SP, Mezuk B, Zandi PP, Strong D, Anthony JC, Niaura R, Uhl GR, Eaton WW: Sex differences in TTC12/ANKK1 haplotype associations with daily tobacco smoking in Black and White Americans. Nicotine Tob Res. 2010 Mar;12(3):251-62. Epub 2010 Feb 4. METHODS: By conducting linkage disequilibrium analyses of 7 informative single nucleotide polymorphisms (SNPs) within the tetratricopeptide repeat domain 12 (TTC12)/ankyrin repeat and kinase containing 1 (ANKK1)/dopamine (D2) receptor gene cluster, we identified haplotype block structures in 270 Black and 368 White (n = 638) participants, from the Baltimore Epidemiologic Catchment Area cohort study, spanning the TTC12 and ANKK1 genes consisting of three SNPs (rs2303380-rs4938015-rs11604671). |
1(0,0,0,1) | Details |
| 19084357 | Perkins KA: Acute responses to nicotine and smoking: implications for prevention and treatment of smoking in lower SES women. Drug Alcohol Depend. 2009 Oct 1;104 Suppl 1:S79-86. Epub 2008 Dec 11. |
0(0,0,0,0) | Details |